Comparing two methods of catheter ablation for ventricular tachycardia in heart disease patients

Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients Withischemic Cardiomyopathy: a Randomized Controlled Study

NA · Rennes University Hospital · NCT05888662

This study is testing if a new way of doing heart surgery can help people with heart disease and ventricular tachycardia feel better and have fewer heart rhythm problems compared to the usual method.

Quick facts

PhaseNA
Study typeInterventional
Enrollment150 (estimated)
Ages18 Years and up
SexAll
SponsorRennes University Hospital (other)
Locations12 sites (Bordeaux and 11 other locations)
Trial IDNCT05888662 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the effectiveness of endo-epicardial catheter ablation compared to traditional endocardial-only ablation for treating ventricular tachycardia in patients with ischemic cardiomyopathy. The study aims to address the high recurrence rates of ventricular tachycardia by targeting both the endocardial and epicardial layers of the heart. Patients will undergo their first radiofrequency ablation procedure, and the outcomes will be monitored to assess the success of the different approaches. The trial includes patients with implantable cardioverter-defibrillators and requires informed consent.

Who should consider this trial

Good fit: Ideal candidates are adults over 18 years old experiencing their first episode of ventricular tachycardia due to ischemic heart disease.

Not a fit: Patients with a history of cardiac surgery that affects the epicardial approach or those who cannot temporarily discontinue anticoagulant therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved outcomes and reduced recurrence of ventricular tachycardia in patients with ischemic heart disease.

How similar studies have performed: While the endo-epicardial approach has been used in other contexts, this specific comparison in ischemic cardiomyopathy is relatively novel and has not been extensively tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients over 18 years of age
2. 1st radiofrequency ablation of VT complicating ischaemic heart disease
3. Patients with an ICD and remote monitoring
4. Having, for women of childbearing age, effective contraception until discharge from hospital
5. Have given their free and informed consent in writing
6. are affiliated to or have health insurance

Exclusion Criteria:

1. History of cardiac surgery compromising the epicardial approach (coronary artery bypass grafting, valve replacements, or other surgeries that may have caused pericardial adhesions)
2. Presence of a left intraventricular thrombus found during pre-procedure imaging
3. Anticoagulant therapy that cannot be temporarily discontinued
4. Double antiplatelet therapy that cannot be temporarily replaced by single antiplatelet therapy
5. History of pericarditis
6. Previous thoracic radiotherapy
7. Contraindication to general anaesthesia
8. Pregnant or breastfeeding woman
9. History of heparin-induced thrombocytopenia type 2 (as injection is required during the procedure)
10. Person under legal protection (safeguard of justice, curatorship, guardianship), deprived of liberty, or unable to express consent

Where this trial is running

Bordeaux and 11 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Ischemic Cardiomyopathy, Catheter Ablation of Ventricular Tachycardia, ischemic cardiomyopathy

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.